We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BeiGene Ltd | NASDAQ:BGNE | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 162.48 | 159.59 | 168.00 | 0 | 09:08:27 |
From May 2021 to May 2024
By Colin Kellaher
BeiGene Ltd. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Brukinsa for the treatment of adults with Waldenstrom's macroglobulinemia, a rare type of non-Hodgkin's lymphoma.
The Beijing biopharmaceutical company said the recommendation covers the treatment of patients who have received at least one prior therapy or the first-line treatment of patients unsuitable for chemo-immunotherapy.
The European Commission, which generally follows CHMP's advice, will now review the recommendation.
BeiGene said approval would be its first in Europe for Brukinsa, which has been cleared in various indications in several countries around the world, including the U.S. and China. BeiGene said its European commercial team is preparing to launch the drug.
American depositary receipts of BeiGene, which closed Thursday at $385.24, rose more than 13% in premarket trading Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 17, 2021 08:35 ET (12:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year BeiGene Chart |
1 Month BeiGene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
